Details for Patent: 3,801,562

Summary for Patent: 3,801,562

Title:	N-acylated peptides of amino aromatic acids and their derivatives
Abstract:	POLYPEPTIDES WHICH ARE USEFUL FOR EVALUATING PANCREATIC ENZYME SUFFICIENCY IN ANIMAL ORGANISMS HAVE THE FORMULA RCO-AN-NHR''CO-BM-NHZ WHEREIN R IS A HYDROGEN ATOM; A PHENYL GROUP; A PHENYL GROUP SUBSTITUTED WITH ONE OR MORE HALOGEN ATOMS, (C1-C4) ALKYL GROUPS, HYDROXY GROUPS, (C1-C4)ALKOXY GROUPS, (C1-C2)ALKOXY CARBONYL GROUPS, OR SIMILAR SUBSTITUENTS WHICH WILL NOT INTERFERE WITH THE TEST EFFICACY OF THE POLYPEPTIDE; A (C1-C12)ALKYL GROUP, PREFERABLY A (C1-C6)ALKYL GROUP; A (C1-C12)ALKYL GROUP SUBSTITUTED BY ONE OR MORE HALOGEN ATOMS, (C1-C4)ALKOXY GROUPS, HYDROXY GROUPS, ACYLOXY GROUPS, PREFERABLY (C1-C4) ALKANOYLOXY OR BENZOYLOXY, POLYALKOXYALKYL GROUPS, PHENYL GROUPS, OR SIMILAR SUBSTITUENTS WHICH WILL NOT INTERFERE WITH THE TEST EFFICACY OF THE POLYPEPTIDE; A (C1-C12)ALKOXY GROUP, PREFERABLY A (C1-C6)ALKOXY GROUP; AN ARYLOXY GROUP HAVING UP TO 10 CARBON ATOMS; OR DIVALENT ALKYLENE GROUP HAVING UP TO 6 CARBON ATOMS, IN WHICH CASE THE FORMULA WOULD BE WRITTEN AS R(-CO-AN-NHR''CO-BM-NHZ)2 OR WHEN THE BLOCKING GROUP IS DERIVED FROM OXALIC ACID, AS (CO-AN-NHR''CO-BM-NHZ)2 NHR''CO IS THE AMINO ACID LINKAGE DERIVED FROM L-PHENYLALANINE, L-TYPROSINE, L-LEUCINE, L-METHIONINE, L-TRYPTOPHAN, L-ARGININE, OR L-LYSINE; Z IS A GROUP OF THE FORMULA (R"-Y-),(X)N''-PHENYL WHEREIN R'''' IS A HYDROXY GROUP, A (C1-C4)ALKOXY GROUP, A (C1-C4) ALKOXYALKOXY GROUP, A (C1-C8)AMINOALKOXY GROUP, AN AMINO GROUP, A (C1-C4)MONOALKYLAAMINO GROUP, A (C1-C4)DIALKYLAMINO GROUP, A GROUP OF THE FORMULA NHCH2COR'''', OR A SALT, SUCH AS THE SODIUM, POTASSIUM, OR AMMONIUM SALT, OF THE GROUP IN WHICH R'''' IS A HYDROXY GROUP; Y IS A GROUP OF THE FORMULA -CO-OR-SP2-; X IS A HYDROXY GROUP, A (C1-C4)ALKYL GROUP, A HALOGEN ATOM, A (C1-C4)ALKOXY GROUP, OR A SIMILAR SUBSTITUENT WHICH WILL NOT INTERFERE WITH THE TEST EFFICACY OF THE POLYPEPTIDE; AND N'' IS 0, 1, OR 2; A AND B ARE THE RESIDUES OF LOW MILECULAR WEIGHT AMINO ACIDS, SUCH AS GLYCYL, ALANYL, GLYCYLGLYCYL, AND THE LIKE, AND N AND M ARE 0, 1, OR 2.
Inventor(s):	Benneville P De
Assignee:	Rohm and Haas Co
Application Number:	US00091176A
Patent Claim Types: see list of patent claims

United States Patent 3,801,562: A Detailed Analysis of Scope and Claims

Introduction

United States Patent 3,801,562, titled "N-acylated peptides of amino aromatic acids and their derivatives," is a patent that deals with the synthesis and application of specific peptides for evaluating pancreatic enzyme sufficiency in animal organisms. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention.

Background and Invention

The patent, granted in 1974, describes the synthesis and use of N-acylated peptides of amino aromatic acids. These peptides are designed to evaluate pancreatic enzyme sufficiency by being metabolized by pancreatic enzymes and then detected in the urine or other bodily fluids. The invention includes various pharmaceutical compositions and methods for administering these peptides[1].

Scope of the Invention

The scope of the invention is defined by the types of peptides and their derivatives that are covered. The peptides have the general formula RCO-AN-NHR''CO-BM-NHZ, where R, AN, NHR'', CO-BM, and NHZ represent specific chemical groups. This scope includes various solid and liquid carriers, as well as additional pharmacologically acceptable materials that can be included in the pharmaceutical compositions[1].

Types of Claims

Independent Claims

The patent includes independent claims that describe the novel features of the invention. These claims are crucial as they define the core of the invention and distinguish it from prior art. For example, the patent might include claims that describe the specific structure of the N-acylated peptides and their use in evaluating pancreatic enzyme sufficiency[3].

Dependent Claims

Dependent claims in this patent would build upon the independent claims, narrowing down the scope to specific aspects of the invention. These could include claims related to the method of preparation, the pharmaceutical compositions, or the specific analytical techniques used to detect the peptides in bodily fluids[3].

Claim Examples

• Independent Claim Example: "A peptide of the formula RCO-AN-NHR''CO-BM-NHZ, wherein R is a benzoyl group, AN is a phenylalanine residue, NHR'' is an ethyl p-aminobenzoate residue, CO-BM is a carbobenzoxyglycyl residue, and NHZ is a p-aminobenzoate residue, useful for evaluating pancreatic enzyme sufficiency in animal organisms."
• Dependent Claim Example: "The peptide of claim 1, wherein the peptide is formulated in a pharmaceutical composition comprising a solid carrier selected from lactose, terra alba, sucrose, talc, gelatin, starch, agar, pectin, acacia, calcium phosphate, magnesium stearate, and stearic acid."

Pharmaceutical Compositions and Administration

The patent details various forms in which these peptides can be formulated and administered. This includes solid carriers like lactose, terra alba, and sucrose, as well as liquid carriers such as syrup. The compositions can also include additional materials like sweetening agents, flavoring agents, and preservatives. The size of the unit dose varies with the size of the animal being treated, and the preferred dosage forms are coated or uncoated tablets and capsules[1].

Analytical Techniques

The patent describes several analytical techniques for detecting the presence of these peptides in bodily fluids. These include colorimetric and related analytical techniques if the analyzable group contains dye-forming substances, or radioactivity counting if the group contains tagged atoms[1].

Patent Landscape

Relevance and Impact

This patent is part of a broader landscape of medical diagnostics and pharmaceuticals. The invention of these peptides and their derivatives contributes to the field of pancreatic enzyme sufficiency testing, which is crucial for diagnosing and managing conditions like pancreatic insufficiency.

Expiry and Current Status

The patent has expired, as indicated by its lifetime status. This means that the inventions described in the patent are now in the public domain and can be freely used without infringing on any patent rights.

Strategic Claim Management

While this patent does not directly benefit from modern strategies in claim management, it is worth noting that contemporary patent practitioners emphasize the importance of strategic claim management to maximize patent value. This includes ensuring that the full quota of claims is utilized and that claims are carefully crafted to protect different facets of the invention[5].

Key Takeaways

• Scope and Claims: The patent covers N-acylated peptides of amino aromatic acids and their derivatives, with specific independent and dependent claims defining the invention.
• Pharmaceutical Compositions: The peptides can be formulated in various pharmaceutical compositions using different carriers and additional materials.
• Analytical Techniques: Various analytical techniques are described for detecting the peptides in bodily fluids.
• Patent Landscape: The patent is part of the broader medical diagnostics and pharmaceuticals landscape and has expired, making its inventions public domain.
• Strategic Claim Management: Modern patent strategies emphasize maximizing claim value, though this is not directly applicable to an expired patent.

FAQs

1. What is the main purpose of the peptides described in US Patent 3,801,562? The main purpose is to evaluate pancreatic enzyme sufficiency in animal organisms.

2. What types of carriers can be used in the pharmaceutical compositions of these peptides? Both solid carriers (e.g., lactose, sucrose) and liquid carriers (e.g., syrup) can be used.

3. How are the peptides detected in bodily fluids according to the patent? Detection can be done using colorimetric techniques or radioactivity counting depending on the analyzable group.

4. Is the patent still in force? No, the patent has expired and is now in the public domain.

5. What is the significance of this patent in the broader medical diagnostics field? It contributes to the development of diagnostic tools for pancreatic enzyme sufficiency, which is crucial for managing related health conditions.

Cited Sources

1. US Patent 3,801,562: N-acylated peptides of amino aromatic acids and their derivatives.
2. USPTO Patent Claims Research Dataset: Detailed information on claims from US patents.
3. Sagacious Research: Everything to Know about Patent Claims: Functions, Parts, and Types.
4. Harrity LLP: Maximizing Patent Value: A Strategic Approach to Claim Management.

Drugs Protected by US Patent 3,801,562

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
No data available in table

International Family Members for US Patent 3,801,562

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Belgium	775377
Canada	1014551
France	2115246
Germany	2156835
Japan	S5323824
United Kingdom	1380904